^
Association details:
Biomarker:NRAS wild-type
Cancer:Rectal Cancer
Drug:Vectibix (panitumumab) (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Rectal cancer: Systemic therapy for advanced or metastatic disease...FOLFOX + panitumumab (KRAS/NRAS/BRAF WT only)...FOLFIRI + panitumumab (KRAS/NRAS/BRAF WT only)...FOLFIRINOX or mFOLFIRINOX + panitumumab...Irinotecan + panitumumab (KRAS/NRAS/BRAF WT only)
Secondary therapy:
FOLFIRI; FOLFOX; irinotecan; FOLFIRINOX